Mark McDonough, CEO of ChromaCode, a molecular diagnostics company, discusses how ChromaCode technology provides a cost-effective, rapid, and accurate method of testing clinically actionable biomarkers. He also talks about the partnership with MedGenome to bring affordable diagnostics to India and the middle east.
Mark has over 25 years of experience helping build high growth HealthCare organizations. He is passionate about his team, his customers, and the patients that he and they are privileged to help serve. He most recently was the CEO of Pierian (now Velsera) which he led to a successful sale to Summa Equity, a private equity firm, in 2022. Prior to Pierian, he led CombiMatrix for five years, culminating in a sale to Invitae in 2017. Over his career, Mark has held various executive and commercial positions, and served as a US Naval Officer.